OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis

Source :: Plus Company Updates. February 16, 2018
Publication Year :: 2018
Abstract: Mississauga, ON: Celgene has issued the following press release: Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active [...]

Subjects :: Celgene Corp. -- Product development
Clinical trials
Ulcerative colitis -- Care and treatment
Pharmaceutical industry -- Product development
General interest
News, opinion and commentary
Otezla (Medication)

Tools